Baker Brothers portfolio, Q1 2026
Baker Bros. Advisors · 13F for the quarter ending Mar 31, 2026
For Q1 2026, Baker Bros. Advisors reported $17.4B across 84 US-listed positions, led by INCY (16.6%), ONC (15.0%) and INSM (7.0%). Compared with its filing for Q4 2025, Baker Brothers opened 7 new positions, added to 18, reduced 6 and sold out of 9; 52 positions did not change.
The largest purchase was an addition to PRAX ($201.9M); the largest sale, the sale of the whole position in RARE ($63.8M).
Key facts
- 13F portfolio value
- $17.4BQ1 2026
- Positions
- 84
- Largest holding
- INCY 16.6%
- New positions
- 7
- Sold out
- 9
- Filed
- May 15, 2026
Holdings as of (Q1 2026), filed with the SEC on . Changes are measured against the filing for Dec 31, 2025. Every tracked investor's Q1 2026 13F.
Bought and sold in Q1 2026
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Praxis Precision MedicinesPRAX | ▲ Added 56% | +626.71K | $201.9M | 1.16% |
| Insmed IncINSM | ▲ Added 13% | +828.37K | $135.5M | 0.78% |
| Grail IncGRAL | ▲ Added 93% | +1.94M | $100.4M | 0.58% |
| Ultragenyx PharmaceuticalRARE | ▼ Sold out | −2.77M | $63.8M | 0.37% |
| Immunocore Holdings plcIMCR | ▼ Reduced 68% | −1.59M | $47.9M | 0.27% |
| Mirum Pharmaceuticals IncMIRM | ▲ New | +445.98K | $41.2M | 0.24% |
Terns Pharmaceuticals Incno ticker on file | ▼ Sold out | −950K | $38.4M | 0.22% |
Crinetics Pharmaceuticalsno ticker on file | ▲ Added 43% | +702.6K | $25.5M | 0.15% |
| Enliven Therapeutics IncELVN | ▲ Added 234% | +633.79K | $24.8M | 0.14% |
| BioNTech SEBNTX | ▼ Reduced 68% | −249.18K | $22.1M | 0.13% |
| BioCryst Pharmaceuticals IncBCRX | ▼ Sold out | −2.82M | $22M | 0.13% |
Ventyx Biosciences Incno ticker on file | ▼ Sold out | −2.35M | $21.2M | 0.12% |
| Evommune IncEVMN | ▲ New | +847.39K | $19.5M | 0.11% |
| Ionis Pharmaceuticals IncIONS | ▲ Added 14% | +255.89K | $19.2M | 0.11% |
| Roivant Sciences LtdROIV | ▼ Reduced 12% | −687.29K | $19M | 0.11% |
| Aktis Oncology IncAKTS | ▲ New | +996.35K | $17.8M | 0.10% |
| Generate Biomedicines IncGENB | ▲ New | +1.42M | $17.8M | 0.10% |
Nuvalent Incno ticker on file | ▼ Sold out | −143.94K | $14.5M | 0.08% |
| Compass Pathways PlcCMPS | ▲ New | +2.34M | $13M | 0.07% |
| Immatics N.V.IMTX | ▼ Reduced 9.7% | −1.18M | $11.6M | 0.07% |
| Arrowhead PharmaceuticalsARWR | ▼ Reduced 8.4% | −182.86K | $11.5M | 0.07% |
| IDEAYA Biosciences IncIDYA | ▲ Added 9.1% | +327.69K | $10.9M | 0.06% |
| Alumis IncALMS | ▲ Added 29% | +450K | $9.9M | 0.06% |
| Revolution Medicines IncRVMD | ▲ Added 1.1% | +100K | $9.7M | 0.06% |
| Abcellera Biologics IncABCL | ▲ Added 10.0% | +2.75M | $9.6M | 0.06% |
| Tectonic Therapeutic IncTECX | ▼ Reduced 33% | −295.61K | $9.1M | 0.05% |
| Eikon Therapeutics IncEIKN | ▲ New | +555.56K | $5.9M | 0.03% |
| Dianthus Therapeutics IncDNTH | ▲ Added 7.9% | +62.41K | $5.2M | 0.03% |
| Design Therapeutics IncDSGN | ▲ Added 16% | +352.88K | $3.8M | 0.02% |
| 4D Molecular TherapeuticsFDMT | ▼ Sold out | −475.74K | $3.6M | 0.02% |
| Wave Life Sciences LtdWVE | ▲ Added 139% | +478.58K | $3.5M | 0.02% |
| CytomX Therapeutics IncCTMX | ▲ Added 17% | +725K | $3.4M | 0.02% |
| Vir Biotechnology IncVIR | ▼ Sold out | −542.54K | $3.3M | 0.02% |
| Arcus Biosciences IncRCUS | ▲ Added 54% | +145.62K | $3.1M | 0.02% |
| Verastem IncVSTM | ▲ New | +584.76K | $3.1M | 0.02% |
| KALA BIO IncKALA | ▼ Sold out | −1.8M | $1M | 0.01% |
| Disc Medicine IncIRON | ▲ Added 3.7% | +12.61K | $806.1K | 0.00% |
| Skye Bioscience IncSKYE | ▲ Added 8.6% | +124.61K | $76.6K | 0.00% |
| Acrivon Therapeutics IncACRV | ▼ Sold out | −22.81K | $55K | 0.00% |
| Incyte CorpINCY | ▲ Added 0.00% | +421 | $39.6K | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q4 2025 |
|---|---|---|---|---|---|---|---|---|
| 1 | Incyte CorpINCY | Health Care | 16.6% | $2.9B | 30.74M | $94.12 | 8+ qtrs | ▲ Added 0.00% |
| 2 | Beone Medicines LtdONC · SPONSORED ADS | Health Care | 15.0% | $2.6B | 8.8M | $296.97 | 8+ qtrs | No change |
| 3 | Insmed IncINSM | Health Care | 6.97% | $1.2B | 7.42M | $163.52 | 8+ qtrs | ▲ Added 13% |
| 4 | Madrigal Pharmaceuticals IncMDGL | Health Care | 6.44% | $1.1B | 2.14M | $523.47 | 8+ qtrs | No change |
| 5 | Acadia Pharmaceuticals IncACAD | — | 5.48% | $954.9M | 42.9M | $22.26 | 8+ qtrs | No change |
| 6 | Revolution Medicines IncRVMD | Health Care | 5.34% | $929.3M | 9.56M | $97.25 | 8+ qtrs | ▲ Added 1.1% |
| 7 | Celcuity IncCELC | — | 5.19% | $903.5M | 7.92M | $114.14 | 8+ qtrs | No change |
| 8 | Kodiak Sciences IncKOD | Health Care | 4.36% | $759.3M | 19.92M | $38.12 | 8+ qtrs | No change |
| 9 | Kymera Therapeutics IncKYMR | Health Care | 4.14% | $721.1M | 8.66M | $83.29 | 8+ qtrs | No change |
| 10 | Summit Therapeutics IncSMMT | Health Care | 3.96% | $690M | 36.39M | $18.96 | 8+ qtrs | No change |
| 11 | Praxis Precision MedicinesPRAX | Health Care | 3.24% | $564.9M | 1.75M | $322.19 | 8+ qtrs | ▲ Added 56% |
| 12 | Rhythm Pharmaceuticals IncRYTM | Health Care | 2.80% | $487.4M | 5.6M | $86.97 | 8+ qtrs | No change |
| 13 | Alkermes PLCALKS · SHS | Health Care | 2.03% | $354M | 10.01M | $35.36 | 8+ qtrs | No change |
| 14 | Grail IncGRAL | Health Care | 1.20% | $208.2M | 4.03M | $51.68 | 6 qtrs | ▲ Added 93% |
| 15 | Edgewise Therapeutics IncEWTX | Health Care | 1.19% | $207.1M | 6.58M | $31.50 | 8+ qtrs | No change |
| 16 | Ionis Pharmaceuticals IncIONS | Health Care | 0.88% | $153.8M | 2.05M | $75.09 | 3 qtrs | ▲ Added 14% |
| 17 | Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL A | Health Care | 0.78% | $136.1M | 2.83M | $48.15 | 8+ qtrs | No change |
| 18 | Immunovant IncIMVT | Health Care | 0.78% | $135.6M | 5.46M | $24.84 | 8+ qtrs | No change |
| 19 | Roivant Sciences LtdROIV · SHS | Health Care | 0.77% | $134.8M | 4.87M | $27.70 | 8+ qtrs | ▼ Reduced 12% |
| 20 | IDEAYA Biosciences IncIDYA | — | 0.76% | $131.5M | 3.95M | $33.32 | 8+ qtrs | ▲ Added 9.1% |
| 21 | Arrowhead PharmaceuticalsARWR | Health Care | 0.72% | $124.9M | 1.99M | $62.70 | 4 qtrs | ▼ Reduced 8.4% |
| 22 | Stoke Therapeutics IncSTOK | — | 0.62% | $108.6M | 3.34M | $32.56 | 8+ qtrs | No change |
| 23 | Immatics N.V.IMTX · SHS | — | 0.62% | $107.4M | 10.92M | $9.84 | 8+ qtrs | ▼ Reduced 9.7% |
| 24 | Abcellera Biologics IncABCL | — | 0.61% | $105.7M | 30.28M | $3.49 | 8+ qtrs | ▲ Added 10.0% |
| 25 | Abivax SAABVX · SPONSORED ADS | Health Care | 0.56% | $97.5M | 875.8K | $111.35 | 3 qtrs | No change |
| 26 | Crinetics Pharmaceuticalsno ticker on file | — | 0.49% | $85.4M | 2.35M | $36.32 | 4 qtrs | ▲ Added 43% |
| 27 | Replimune Group IncREPL | — | 0.49% | $84.5M | 11.05M | $7.65 | 8+ qtrs | No change |
| 28 | Celcuity Incno ticker on file · NOTE 2.75% 8/1/2031 | — | 0.43% | $74.9M | 30.75M | $2.43 | 3 qtrs | — |
| 29 | Nurix Therapeutics IncNRIX | — | 0.42% | $72.2M | 4.66M | $15.50 | 8+ qtrs | No change |
| 30 | Denali Therapeutics IncDNLI | — | 0.41% | $71.6M | 3.73M | $19.20 | 8+ qtrs | No change |
| 31 | Dianthus Therapeutics IncDNTH | Health Care | 0.41% | $71.5M | 852.16K | $83.92 | 4 qtrs | ▲ Added 7.9% |
| 32 | Monte Rosa Therapeutics IncGLUE | — | 0.41% | $71.5M | 4.35M | $16.45 | 8+ qtrs | No change |
| 33 | Structure Therapeutics IncGPCR · SPONSORED ADS | — | 0.40% | $69M | 1.43M | $48.20 | 7 qtrs | No change |
| 34 | Entrada Therapeutics IncTRDA | — | 0.37% | $64M | 5.07M | $12.62 | 8+ qtrs | No change |
| 35 | Bicycle Therapeutics PlcBCYC · SPONSORED ADS | — | 0.29% | $50.5M | 10.89M | $4.64 | 8+ qtrs | No change |
| 36 | Spyre Therapeutics IncSYRE | Health Care | 0.29% | $50.4M | 1M | $50.44 | 4 qtrs | No change |
| 37 | Rapport Therapeutics IncRAPP | — | 0.28% | $48.4M | 1.55M | $31.29 | 4 qtrs | No change |
| 38 | Alumis IncALMS | — | 0.26% | $44.3M | 2.01M | $22.03 | 8+ qtrs | ▲ Added 29% |
| 39 | Mirum Pharmaceuticals IncMIRM | Health Care | 0.24% | $41.2M | 445.98K | $92.38 | 1 qtr | New |
| 40 | Viridian Therapeutics IncVRDN | — | 0.22% | $38.6M | 1.97M | $19.56 | 4 qtrs | No change |
| 41 | Enliven Therapeutics IncELVN | — | 0.20% | $35.5M | 905.19K | $39.20 | 8+ qtrs | ▲ Added 234% |
| 42 | Prelude Therapeutics IncPRLD | — | 0.20% | $34.6M | 10.12M | $3.42 | 8+ qtrs | No change |
| 43 | Dbv Technologies S A SponsoredDBVT · SPONSORED ADS | — | 0.18% | $30.5M | 1.46M | $20.89 | 8+ qtrs | No change |
| 44 | Design Therapeutics IncDSGN | — | 0.16% | $27.5M | 2.59M | $10.64 | 8+ qtrs | ▲ Added 16% |
| 45 | Centessa Pharmaceuticals PLCno ticker on file · SPONSORED ADS | — | 0.15% | $26.6M | 670.75K | $39.72 | 2 qtrs | No change |
| 46 | CytomX Therapeutics IncCTMX | — | 0.13% | $23.4M | 4.98M | $4.70 | 4 qtrs | ▲ Added 17% |
| 47 | Jade Biosciences IncJBIO | — | 0.13% | $23.1M | 1.64M | $14.05 | 2 qtrs | No change |
| 48 | Disc Medicine IncIRON | — | 0.13% | $22.4M | 349.66K | $63.94 | 6 qtrs | ▲ Added 3.7% |
| 49 | Immunocore Holdings plcIMCR · ADS | — | 0.13% | $22.1M | 734.4K | $30.15 | 8+ qtrs | ▼ Reduced 68% |
| 50 | Xenon Pharmaceuticals IncXENE | — | 0.12% | $21.5M | 370.21K | $58.15 | 8+ qtrs | No change |
| 51 | Celldex Therapeutics IncCLDX | — | 0.12% | $21.1M | 665.37K | $31.72 | 8+ qtrs | No change |
| 52 | Neurogene IncNGNE | — | 0.12% | $20M | 991.69K | $20.16 | 8+ qtrs | No change |
| 53 | Evommune IncEVMN | — | 0.11% | $19.5M | 847.39K | $22.99 | 1 qtr | New |
| 54 | Tectonic Therapeutic IncTECX | — | 0.11% | $18.8M | 607.79K | $30.91 | 5 qtrs | ▼ Reduced 33% |
| 55 | Contineum Therapeutics IncCTNM · CL A | — | 0.11% | $18.6M | 1.42M | $13.06 | 8+ qtrs | No change |
| 56 | argenx SEARGX · SPONSORED ADR | Health Care | 0.11% | $18.4M | 25.17K | $730.25 | 8+ qtrs | No change |
| 57 | Cerus CorpCERS | — | 0.11% | $18.2M | 10.01M | $1.82 | 8+ qtrs | No change |
| 58 | Taysha Gene Therapies IncTSHA | — | 0.10% | $17.9M | 4M | $4.47 | 8+ qtrs | No change |
| 59 | Aktis Oncology IncAKTS | — | 0.10% | $17.8M | 996.35K | $17.89 | 1 qtr | New |
| 60 | Generate Biomedicines IncGENB | — | 0.10% | $17.8M | 1.42M | $12.50 | 1 qtr | New |
| 61 | Sionna Therapeutics IncSION | — | 0.09% | $16M | 400K | $40.09 | 5 qtrs | No change |
| 62 | Dyne Therapeutics IncDYN | — | 0.09% | $14.7M | 813.45K | $18.13 | 2 qtrs | No change |
| 63 | Xencor IncXNCR | — | 0.08% | $13.3M | 1.1M | $12.06 | 8+ qtrs | No change |
| 64 | Compass Pathways PlcCMPS · SPONSORED ADS | — | 0.07% | $13M | 2.34M | $5.53 | 1 qtr | New |
| 65 | Relay Therapeutics IncRLAY | — | 0.07% | $11.5M | 1.16M | $9.95 | 8+ qtrs | No change |
| 66 | Sera Prognostics IncSERA · CLASS A COM | — | 0.06% | $11.2M | 5.5M | $2.03 | 8+ qtrs | No change |
| 67 | BioNTech SEBNTX · SPONSORED ADS | Health Care | 0.06% | $10.6M | 119.74K | $88.88 | 6 qtrs | ▼ Reduced 68% |
| 68 | Pharvaris N VPHVS | — | 0.06% | $10.6M | 375K | $28.25 | 3 qtrs | No change |
| 69 | Arcus Biosciences IncRCUS | — | 0.05% | $9M | 415.62K | $21.60 | 2 qtrs | ▲ Added 54% |
| 70 | Maplight Therapeutics IncMPLT | — | 0.04% | $7.4M | 364.71K | $20.33 | 2 qtrs | No change |
| 71 | Absci CorpABSI | — | 0.04% | $6.4M | 2.13M | $3.00 | 2 qtrs | No change |
| 72 | Wave Life Sciences LtdWVE · SHS | — | 0.03% | $6M | 822.64K | $7.25 | 7 qtrs | ▲ Added 139% |
| 73 | vTv Therapeutics IncVTVT · CL A | — | 0.03% | $5.9M | 148.31K | $39.66 | 8+ qtrs | No change |
| 74 | Eikon Therapeutics IncEIKN | — | 0.03% | $5.9M | 555.56K | $10.58 | 1 qtr | New |
| 75 | Protara Therapeutics IncTARA | — | 0.03% | $5.1M | 971.61K | $5.21 | 8+ qtrs | No change |
| 76 | Sagimet Biosciences IncSGMT | — | 0.03% | $5M | 953K | $5.22 | 8+ qtrs | No change |
| 77 | LB Pharmaceuticals IncLBRX | — | 0.03% | $4.9M | 200K | $24.66 | 3 qtrs | No change |
| 78 | Verastem IncVSTM | — | 0.02% | $3.1M | 584.76K | $5.30 | 1 qtr | New |
| 79 | TScan Therapeutics IncTCRX | — | 0.02% | $2.8M | 2.78M | $1.01 | 8+ qtrs | No change |
| 80 | Skye Bioscience IncSKYE | — | 0.01% | $968.1K | 1.58M | $0.6146 | 8+ qtrs | ▲ Added 8.6% |
| 81 | Sana Biotechnology IncSANA | — | 0.01% | $894.2K | 310.48K | $2.88 | 8+ qtrs | No change |
| 82 | Aligos Therapeutics IncALGS | — | 0.00% | $617.1K | 83.06K | $7.43 | 8+ qtrs | No change |
| 83 | Tyra Biosciences IncTYRA | — | 0.00% | $406.2K | 10.61K | $38.30 | 8+ qtrs | No change |
| 84 | Surrozen Incno ticker on file · W EXP 8/11/2026 | — | 0.00% | $13.3K | 833.33K | $0.0160 | 8+ qtrs | No change |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 78.9% | $13.7B | 24 |
| No sector on file | 21.1% | $3.7B | 60 |
Questions and answers
What did Baker Brothers own in Q1 2026?
Baker Bros. Advisors's 13F for Q1 2026 lists 84 positions worth $17.4B. The largest: INCY (16.6%), ONC (15.0%), INSM (7.0%), MDGL (6.4%), ACAD (5.5%).
What did Baker Brothers buy in Q1 2026?
The largest purchases, by the shares bought at the quarter-end price the filing implies: PRAX (added, $201.9M), INSM (added, $135.5M), GRAL (added, $100.4M), MIRM (new, $41.2M), Crinetics Pharmaceuticals (added, $25.5M), ELVN (added, $24.8M).
What did Baker Brothers sell in Q1 2026?
The largest sales: RARE (sold out, $63.8M), IMCR (reduced, $47.9M), Terns Pharmaceuticals Inc (sold out, $38.4M), BNTX (reduced, $22.1M), BCRX (sold out, $22M), Ventyx Biosciences Inc (sold out, $21.2M).
When was this filing made?
Baker Bros. Advisors filed its 13F for the quarter ending Mar 31, 2026 on May 15, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Baker Brothers portfolio, Q1 2026: Baker Bros. Advisors 13F holdings”, data as of 15 May 2026. https://funkfolio.com/gurus/baker-brothers/2026-q1
Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Mar 31, 2026.
Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Mar 31, 2026, filed May 15, 2026. Changes compare share counts with the filing for Dec 31, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $17.4B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 8 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.